Literature DB >> 8489328

Dissociation between pituitary and adrenal suppression to dexamethasone in depression.

E A Young1, J Kotun, R F Haskett, L Grunhaus, J F Greden, S J Watson, H Akil.   

Abstract

OBJECTIVE: To determine if corticotroph nonsuppression, as reflected by beta-endorphin nonsuppression, occurs before cortisol nonsuppression (defined as a cortisol level of > 140 nmol/L) when examining multiple time points in a day.
SETTING: The General Medical Clinical Research Center and Inpatient Depression Research Unit, Ann Arbor, Mich.
DESIGN: Multiple blood samples were obtained through an intravenous catheter around the time points of 8 AM, noon, and 4 PM and assayed for beta-endorphin and cortisol. PATIENTS: Patients meeting Research Diagnostic Criteria for the diagnosis of major depressive disorder, primary and simple. A total of 73 subjects, both inpatients and outpatients, were studied. INTERVENTION: Samples were obtained both at baseline and 1 day after administration of 1 mg of dexamethasone at 11:30 PM. MEASUREMENTS AND
RESULTS: Overall 39 patients (53%) demonstrated beta-endorphin nonsuppression after administration of dexamethasone at any of the three time points, while only eight patients (11%) demonstrated cortisol nonsuppression at any of these time points. Cortisol nonsuppression, but not beta-endorphin nonsuppression, was associated with lower concentrations of dexamethasone in plasma. Baseline cortisol and menopausal status were significantly associated with beta-endorphin nonsuppression in women.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8489328     DOI: 10.1001/archpsyc.1993.01820170073010

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  7 in total

Review 1.  Sex differences in the hypothalamic-pituitary-adrenal axis: An obstacle to antidepressant drug development?

Authors:  Nikolaos Kokras; Georgia E Hodes; Debra A Bangasser; Christina Dalla
Journal:  Br J Pharmacol       Date:  2019-06-26       Impact factor: 8.739

2.  Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders.

Authors:  Fabrice Duval; Marie-Claude Mokrani; Alexis Erb; Vlad Danila; Felix Gonzalez Lopera; Ludovic Jeanjean
Journal:  Front Psychiatry       Date:  2020-09-18       Impact factor: 4.157

3.  Subgenual prefrontal cortex activity predicts individual differences in hypothalamic-pituitary-adrenal activity across different contexts.

Authors:  Allison L Jahn; Andrew S Fox; Heather C Abercrombie; Steven E Shelton; Terrence R Oakes; Richard J Davidson; Ned H Kalin
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

Review 4.  Innovative approaches for the treatment of depression: targeting the HPA axis.

Authors:  Fiona Thomson; Mark Craighead
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

Review 5.  Cortisol and Major Depressive Disorder-Translating Findings From Humans to Animal Models and Back.

Authors:  L Sanjay Nandam; Matthew Brazel; Mei Zhou; Dhanisha J Jhaveri
Journal:  Front Psychiatry       Date:  2020-01-22       Impact factor: 4.157

6.  Intranasal Administration of Melanin-Concentrating Hormone Reduces Stress-Induced Anxiety- and Depressive-Like Behaviors in Rodents.

Authors:  Ju-Young Oh; Quan Feng Liu; Cai Hua; Ha Jin Jeong; Jae-Hwan Jang; Songhee Jeon; Hi-Joon Park
Journal:  Exp Neurobiol       Date:  2020-12-31       Impact factor: 3.261

Review 7.  Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression.

Authors:  Wayne C Drevets; Joseph L Price; Maura L Furey
Journal:  Brain Struct Funct       Date:  2008-08-13       Impact factor: 3.270

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.